当前位置: X-MOL 学术Org. Process Res. Dev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 2. Strategic Selections in the Transition from an Enabling Route to a Commercial Synthesis
Organic Process Research & Development ( IF 3.1 ) Pub Date : 2017-08-09 00:00:00 , DOI: 10.1021/acs.oprd.7b00121
Ke Chen 1 , Christina Risatti 1 , James Simpson 1 , Maxime Soumeillant 1 , Michelle Soltani 1 , Michael Bultman 1 , Bin Zheng 1 , Boguslaw Mudryk 1 , Jonathan C. Tripp 1 , Thomas E. La Cruz 1 , Yi Hsiao 1 , David A. Conlon 1 , Martin D. Eastgate 1
Affiliation  

During the process of developing a synthesis to a complex molecule, multiple decisions are made regarding the strategies and tactics used to prepare key bonds. In this article, we preface a series of papers describing the development of the commercial synthesis of BMS-663068 (a potential new treatment for HIV), with an in-depth discussion of the important strategic decisions made during the process of designing and demonstrating the proposed commercial synthesis of this complex clinical candidate. We discuss the key strategic disconnections and the key experimental data used to drive our tactical decisions during development. In the remaining articles in this series, we outline the development of these enabling chemical processes into scalable procedures ready to support commercialization of this promising new medicine.

中文翻译:

HIV附着抑制剂BMS-663068的制备。第2部分。从使能路线到商业综合的过渡中的战略选择

在将合成物发展为复杂分子的过程中,对于用于制备关键键的策略和策略做出了多个决策。在本文中,我们将介绍一系列描述BMS-663068(一种潜在的HIV新疗法)商业合成方法的发展的论文,并深入讨论在设计和演示BMS-663068的过程中做出的重要战略决策。提出了该复杂临床候选药物的商业合成。我们讨论了关键的战略脱节和关键的实验数据,这些数据用于在开发过程中推动我们的战术决策。在本系列的其余文章中,我们概述了将这些使能的化学过程发展为可扩展程序的过程,这些程序可支持该有前途的新药的商业化。
更新日期:2017-08-09
down
wechat
bug